H+C supported argenx’s first Phase 3 data unblinding of the Company’s lead product candidate for a rare neuromuscular disease. Activities included messaging and internal and external communications support to reach investors, doctors and the patient community. H+C secured more than 40 stories in top-tier, business and trade media including STAT, Bloomberg and Fierce Biotech.